This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 2, 2008
Last updated: April 26, 2012
Last verified: April 2012
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone

Condition Intervention Phase
Non Small Cell Lung Cancer Lung Cancer Drug: ZD4054 Drug: Pemetrexed Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Time to Death [ Time Frame: Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010). ]
    Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)

Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation ]
    Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method

Enrollment: 66
Study Start Date: August 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
ZD4054 + Pemetrexed
Drug: ZD4054
10mg oral tablet, once daily
Other Name: Zibotentan
Drug: Pemetrexed
500mg2/m IV infusion
Other Name: Alimta
Placebo Comparator: 2
ZD4054 matched placebo + pemetrexed
Drug: Pemetrexed
500mg2/m IV infusion
Other Name: Alimta
Drug: Placebo
10mg oral tablet, once daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy
  • Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy
  • Life expectancy of > 12 weeks

Exclusion Criteria:

  • Prior treatment with pemetrexed in the last 12 months.
  • Prior therapy with an ET receptor antagonist
  • Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00745875

research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Czech Republic
Research Site
Jicin, Czech Republic
Research Site
Prague, Czech Republic
Research Site
Cedex, France
Research Site
Strasbourg, France
Research Site
Bucharest, Romania
Research Site
Cluj-Napoca, Romania
Research Site
Chernivtsi, Ukraine
Research Site
Kiev, Ukraine
Research Site
Sumy, Ukraine
Research Site
Uzngorod, Ukraine
Sponsors and Collaborators
Study Director: Thomas Morris, MD AstraZeneca
Principal Investigator: Christos Chouaid, MD, Prof Hospital Saint-Antoine, Cedex, France
  More Information

Responsible Party: AstraZeneca Identifier: NCT00745875     History of Changes
Other Study ID Numbers: D4320C00035
Study First Received: September 2, 2008
Results First Received: April 26, 2012
Last Updated: April 26, 2012

Keywords provided by AstraZeneca:
Phase II
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on September 21, 2017